US10632018B2 - Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability - Google Patents

Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability Download PDF

Info

Publication number
US10632018B2
US10632018B2 US15/642,833 US201715642833A US10632018B2 US 10632018 B2 US10632018 B2 US 10632018B2 US 201715642833 A US201715642833 A US 201715642833A US 10632018 B2 US10632018 B2 US 10632018B2
Authority
US
United States
Prior art keywords
subsystem
oxygen
control
oxygen production
flow rate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US15/642,833
Other versions
US20170296392A1 (en
Inventor
Michael C. Wells
Mark Parker
Daniel J. Clarius
Andrew Parker
Faraidoon Pundole
Tom Woods
Mark Q. Niederauer
James P. DALEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Electrochemical Oxygen Concepts Inc
Original Assignee
Electrochemical Oxygen Concepts Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrochemical Oxygen Concepts Inc filed Critical Electrochemical Oxygen Concepts Inc
Priority to US15/642,833 priority Critical patent/US10632018B2/en
Publication of US20170296392A1 publication Critical patent/US20170296392A1/en
Assigned to ELECTROCHEMICAL OXYGEN CONCEPTS, INC. reassignment ELECTROCHEMICAL OXYGEN CONCEPTS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DALEY, JAMES P., NIEDERAUER, MARK, WELLS, MICHAEL C., CLARIUS, DANIEL J., PARKER, ANDREW, PARKER, MARK, PUNDOLE, FARAIDOON, WOODS, TOM
Application granted granted Critical
Publication of US10632018B2 publication Critical patent/US10632018B2/en
Assigned to VGM GROUP INC. reassignment VGM GROUP INC. SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ELECTROCHEMICAL OXYGEN CONCEPTS, INC.
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/00051Accessories for dressings
    • A61F13/00068Accessories for dressings specially adapted for application or removal of fluid, e.g. irrigation or drainage of wounds, under-pressure wound-therapy
    • A61F13/05
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00Devices for applying media, e.g. remedies, on the human body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00Devices for applying media, e.g. remedies, on the human body
    • A61M35/003Portable hand-held applicators having means for dispensing or spreading integral media
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00Devices for applying media, e.g. remedies, on the human body
    • A61M35/30Gas therapy for therapeutic treatment of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00089Wound bandages
    • A61F2013/0017Wound bandages possibility of applying fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00089Wound bandages
    • A61F2013/0017Wound bandages possibility of applying fluid
    • A61F2013/00174Wound bandages possibility of applying fluid possibility of applying pressure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00089Wound bandages
    • A61F2013/00187Wound bandages insulating; warmth or cold applying
    • A61F2013/002Wound bandages insulating; warmth or cold applying with temperature control
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00089Wound bandages
    • A61F2013/00246Wound bandages in a special way pervious to air or vapours
    • A61F2013/00268Wound bandages in a special way pervious to air or vapours impervious, i.e. occlusive bandage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00365Plasters use
    • A61F2013/00536Plasters use for draining or irrigating wounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00365Plasters use
    • A61F2013/0054Plasters use for deep wounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00727Plasters means for wound humidity control
    • A61F2013/00731Plasters means for wound humidity control with absorbing pads
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00855Plasters pervious to air or vapours
    • A61F2013/00872Plasters pervious to air or vapours with controlled oxygen permeability
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00902Plasters containing means
    • A61F2013/0094Plasters containing means for sensing physical parameters
    • A61F2013/00953Plasters containing means for sensing physical parameters temperature
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00902Plasters containing means
    • A61F2013/0094Plasters containing means for sensing physical parameters
    • A61F2013/00957Plasters containing means for sensing physical parameters pressure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00902Plasters containing means
    • A61F2013/0094Plasters containing means for sensing physical parameters
    • A61F2013/0097Plasters containing means for sensing physical parameters oxygen content

Definitions

  • This invention relates to tissue treatment systems, specifically to non-invasive tissue oxygenation systems for accelerating the healing of damaged tissue and promoting tissue viability.
  • tissue treatment systems specifically to non-invasive tissue oxygenation systems for accelerating the healing of damaged tissue and promoting tissue viability.
  • a wound results and a four phase healing process begins.
  • Optimal metabolic function of these cells to repopulate the wound requires that oxygen be available for all phases of wound healing. The more layers of tissue that are damaged the greater the risk for complications to occur in the wound healing process.
  • Difficult-to-heal wounds encounter barriers to the wound healing process and typically experience delays in one or more of the last three phases of wound healing.
  • One of the most common contributing factors to venous leg ulcers, diabetic foot ulcers and pressure ulcers experiencing delays in the healing process is the problem of chronic wound ischemia.
  • Chronic wound ischemia a pathological condition that restricts blood supply, oxygen delivery and blood request for adequate oxygenation of tissue, inhibiting normal wound healing.
  • an advanced wound dressing or combination of advanced wound dressings providing a dressing treatment system.
  • An advanced dressing is positioned on the wound site or on the wound site and the surrounding intact skin providing a wound site enclosure.
  • An advanced wound dressing is typically comprised of materials having properties for promoting moist wound healing, managing wound exudate and helping control wound bioburden.
  • the typical material components in combination further include properties for providing limited moisture vapor permeability. The lower the dressing's moisture vapor permeability or more occlusive the dressing the lower the amount of ambient air and the respective lower amount of oxygen is thereby available to the wound bed. 100% oxygen exerts a partial pressure of 760 mm Hg.
  • Ambient air is comprised of about 21% oxygen thereby exerting a partial pressure of oxygen at about 159 mm Hg.
  • a typical advanced wound dressing or wound dressing system comprised of lower moisture vapor permeable materials impacts the available oxygen for the wound site thereby limiting the partial pressure of oxygen at the enclosed wounds site at about 10 mm Hg to 60 mm Hg.
  • Fresh air is provided to the wound site only when the dressing is changed.
  • a dressing may remain covering the wound site for up to seven days before a dressing change is required.
  • the moisture vapor permeability property of an advanced wound dressing providing a reduced oxygen wound environment thereby works against the optimal metabolic function of cells to repopulate the wound which requires that oxygen be available for all phases of wound healing.
  • Prior art methods of tissue oxygenation for difficult-to-heal wounds include topical hyperbaric oxygen applied intermittently or continuously.
  • Intermittent topical hyperbaric oxygen is a method of tissue oxygenation comprising of a sealed extremity or partial body chamber and a connected source of high flow pure oxygen whereby the affected limb or affected body area is positioned in a sealed extremity chamber or partial body chamber so that the oxygen source supplying the chamber is providing the patient topically up to 100% oxygen at flow rates that may exceed 300 liters per hour pressurizing the interior of the chamber up to 1.05% normal atmospheric pressure thereby increasing the available oxygen for cellular processing at affected wound site.
  • the partial pressure of oxygen exerted inside the topical or partial body chamber may attain 798 mm Hg.
  • Topical hyperbaric oxygen is applied for about 90 minutes.
  • Prior art also teaches a plurality of methods to apply topically hyperbaric oxygen intermittently.
  • a partial body chamber for treating sacral wounds has been described in U.S. Pat. No. 4,328,799 to LoPiano (1980) whereby oxygen is applied from a stationary supply tank into the interior of the chamber through connected tubing.
  • a similar method of applying topical hyperbaric oxygen is described in U.S. Pat. No. 5,478,310 to Dyson-Cantwell (1995) whereby oxygen is applied from a stationary supply tank into the interior of the disposable extremity chamber through connected tubing.
  • Prior art describes disposable devices are either “on or off.”
  • the prior art describes disposable devices without means to sense temperature changes in the wound site oxygen environment.
  • Prior art does not provide a means to deliver a varying (adjustable) oxygen flow rate without requiring the patient to obtain and apply a new device with a new battery having a specific amperage. Additional limitations are also associated with the use of a fixed non-variable oxygen flow rate.
  • No prior art low dose tissue oxygenation device provides continuous oxygen adjustability to a patient's wound(s) creating a controlled hyperoxia and hypoxia wound environment for damaged tissue to accelerate wound healing and promote tissue viability.
  • nothing in the prior art teaches continuous oxygen adjustability based on actual flow rate, partial pressures at the wound site, and temperatures at the wound site.
  • the invention is an improved low dose tissue oxygenation device and wound monitoring system.
  • the present invention generally comprises an oxygen delivery tube for placement at the wound bed and a wound dressing covering the tubing and wound site for restricted air flow enclosure.
  • the tubing may have multiple holes at or near the distal end of the tubing.
  • the tubing may include a generally flat, flexible, oxygen-permeable tape or membrane section attached at the distal end of the tube.
  • the tubing may be flexible with a kink resistant inner lumen.
  • the tubing may have a temperature sensor.
  • the tubing may have a pressure sensor.
  • the tubing may include a partial pressure of oxygen sensor. The proximal end of the tubing is connected to a source of oxygen.
  • the proximal end of the tubing may have a port Leur-type locking mechanism for an airtight seal during application of the oxygen and for removal from the oxygen source during application a dressing.
  • a source of oxygen is in communication with the proximal and distal ends of the tube.
  • a source of oxygen may be an electrochemical oxygen concentrator supplied by alternating or direct current, a power management device and its power management protocol.
  • the variable electrochemical oxygen concentrator is used in accordance with the present invention by varying the oxygen flow rate to meet varying target parameters at the wound site.
  • the oxygen flow rate is adjusted by a system that periodically or continuously monitors the wound bed pressure and temperature environment or the tubing pressure and adjusting the oxygen flow rate in accordance to target set points. Adjusting oxygen flow in response to monitored changes in wound site oxygen and target oxygen pressure and temperature protocols provides a controlled hyperoxia wound environment which may shorten the healing process.
  • the device may have a backlight display terminal or touch screen liquid crystal display, a data input key pad or device function control buttons, a wound temperature monitoring system, a battery or oxygen pressure alarm system, a digital camera, a patient data input and memory system and/or a data port or wireless data access.
  • FIG. 1 is a perspective view of an embodiment of a tissue oxygenation system of the present invention.
  • FIG. 1A is a cross section view of a wound site showing a distal end of a oxygen delivery tube of the present invention
  • FIG. 2 is a side perspective view of the distal end of an embodiment of the tubing of the present invention showing a generally flat, flexible, oxygen-permeable tape or membrane section affixed to the tubing.
  • FIG. 2A is an end view of another embodiment of the tubing of the present invention.
  • FIG. 3 is side elevation view of the distal end of the oxygen delivery tubing of the embodiment of FIG. 2A of the present invention
  • FIG. 4 is a perspective view of a handset of the present invention.
  • FIG. 5 is a flow chart illustrating the process of the present invention.
  • FIG. 6 is a top plan view of the electrolyzer/concentrator of the present invention.
  • FIG. 6A is a side elevation plan view of the electrolyzer of FIG. 6 .
  • FIG. 6B is an exploded perspective view of the electrolyzer of FIG. 6 .
  • FIG. 7 is a processor firmware flow chart of the present invention.
  • tissue oxygenation system for the healing of damaged tissue and to promote tissue viability
  • FIG. 1 is a perspective view of several primary components of the present invention according to the preferred embodiment.
  • the present invention includes a monitoring unit 10 , an electrochemical oxygen concentrator 11 , oxygen delivery tubing 12 , moisture absorbent dressing 14 , and vapor dressing 16 .
  • oxygen delivery tubing 12 is connected at the proximal end 15 of the long, kink resistant tubing to the monitoring unit 10 .
  • the monitoring unit 10 has a small, lightweight housing which is portable and may be discretely worn by the patient in a pocket or attached to a belt.
  • the monitoring unit 10 includes within the housing 13 a microprocessor 58 (see FIGS. 5 and 7 ), a power management system 52 , pressure 56 and temperature 57 sensor interface(s), a flow rate sensor 54 , an input port 62 and a user entry port 66 .
  • the electrochemical oxygen concentrator 11 is disposed within the housing 13 .
  • the microprocessor 58 functions to control power, collect various readings from the flow, pressure, and temperature sensors controls ionic purification of room air by the electrochemical oxygen concentrator for delivery to the tubing, and controls the informational display on the monitoring unit 10 .
  • the microprocessor 58 is capable of receiving data through the user entry port and the input port, including information related to specific patients and re-programming information if there is a system malfunction with the device.
  • the distal end 17 of the tubing 12 has a soft, flexible, oxygen permeable tape or membrane section 29 placed on the damaged tissue or wound site 20 of a patient's limb 19 covered with a moisture absorbent dressing 14 and further covered by a reduced vapor pressure, permeable, occlusive dressing 16 .
  • oxygen is delivered to the wound site 20 through a kink-resistant tube 12 connected at the proximal end 15 to the outlet of the oxygen concentrator at the monitor unit housing.
  • a kink-resistant tube 12 connected at the proximal end 15 to the outlet of the oxygen concentrator at the monitor unit housing.
  • soft, flexible oxygen-permeable flat tape or membrane 29 On the distal end 17 of the tubing 12 is connected soft, flexible oxygen-permeable flat tape or membrane 29 .
  • Extending through the lumen of the tube are several sensor wires 30 and 32 . These wires communicate from temperature sensor 30 a and oxygen partial pressure sensor 32 a disposed at the wound site to temperature 57 and pressure 56 transducers in the monitoring unit with the transducers providing input to the microprocessor 58 as would be understood by one of ordinary skill in the art.
  • tubing 12 a ( FIG. 2A ) preferably has several lumens, pressure 21 and temperature 19 sensors, and other such sensors as may be required to effectively monitor wound treatment, disposed therein.
  • FIG. 2A illustrates an end view of the tubing 12 a , and depicts a tubing with a length capable of connecting to the output side of electrochemical oxygen concentrator 11 housed within monitoring unit 10 .
  • Such tubing lengths allow the monitoring unit to be worn discretely and continuously deliver oxygen to the wound site 20 .
  • An inner lumen, or bore 18 a , of the tubing is a star like configuration to prevent kinking of the tubing and still allows oxygen flow if bent.
  • the oxygen partial pressure sensor 19 a at the wound site is disposed within the tubing and is in communication with a pressure monitoring system including transducer 58 allowing for oxygen flow rate adjustment, visual pressure display, and out of range alarm.
  • a temperature sensor 21 a is also disposed within the tubing at the wound site 20 and is in communication with a temperature monitoring system including transducer 57 allowing for visual display of temperature, an out of range alarm, and allowing for oxygen adjustment via the microprocessor 58 as is appropriate.
  • FIG. 3 is a side view of the distal end of alternative tubing 12 a , which includes a plurality of holes 23 formed along the side of the distal end of the tubing to aid in the delivery of oxygen to the wound.
  • the oxygen flows F through the tubing to the wound site and may enter the wound bed through the multiple holes 23 .
  • the oxygen may also flow through the distal end of star shaped lumen 18 a , however, the multiple holes at the distal end of the tubing allow for improved flow of oxygen to the wound site 20 .
  • FIG. 1A shows a wound site 20 , with the distal end 17 of the oxygen delivery tubing 12 having the oxygen distribution tape 29 placed over the wound site 20 .
  • the tape 29 is placed centrally on the wound site for optimal delivery of oxygen to the damaged tissue.
  • a moisture absorbent dressing 14 is placed at the wound site covering the tape end of the oxygen delivery tubing 12 and wound site.
  • moisture absorbent dressing is typical standard of care protocol for a difficult-to-heal wound.
  • a reduced moisture vapor permeable dressing 16 covers the moisture absorbent dressing 14 , tape end of tubing 12 and wound site 20 , creating a restricted airflow enclosure.
  • the reduced moisture vapor permeable dressing 16 is transparent and may be described to as an occlusive dressing.
  • the occlusive dressing traps the oxygen over the wound site to create and maintain oxygen rich environment.
  • the local partial pressure of oxygen at the wound site 20 may be increased from a low range of 10 to 60 mm Hg to an oxygen rich environment range of 200 to 760 mm HG.
  • the increased available oxygen is metabolized at the cellular level and will stimulate an increase in growth factors, epithelialization, granulation tissue, glycosaminoglycan production, and collagen synthesis.
  • the oxygen partial pressure at the wound site is communicated to the pressure monitoring transducer 57 in the housing 13 .
  • the transducer supplies data to the microprocessor 58 which controls the power flow (amperage) to the concentrator 11 .
  • the concentrator may increase or decrease the O 2 flow rate.
  • FIG. 4 is a perspective view of a handset housing the major components of the present invention.
  • FIG. 5 is a flow chart of the present invention.
  • the monitor housing 13 draws in room air 50 with about 21% oxygen through the air inlet 40 by means of an electrochemical process.
  • the room air passes through an ion exchange oxygen concentrator 11 , which concentrates the oxygen level of the room air to create a mixture that is 99% pure oxygen.
  • the power management system 52 controls the electrical current supplied to the ion exchange oxygen concentrator 11 , thereby making the oxygen flow rate conform to the amount of current supplied to the ion exchange oxygen concentrator, i.e., increasing electrical current increases the electrochemical process and thereby increases the respective oxygen flow rate to the wound site 20 and decreasing the electrical current decreases the electrochemical process thereby decreasing the respective oxygen flow rate to the wound site.
  • the power management system 52 includes lithium batteries (7.4 v) and a regulator which varies the amperage over a range from approximately 15 milliamps to approximately 150 milliamps. This range of current variation results in O 2 flow rates in the range of approximately 1.0 milliliters/hour to approximately 15.0 milliliters/hour.
  • the concentrated O 2 then exits the housing through the oxygen delivery port 54 .
  • the proximal end 15 of the oxygen delivery tubing 12 is connected with an oxygen delivery port 54 with Leur-type locking fitting.
  • the locking fitting is engaged to maintain an airtight seal with the tubing.
  • a pressure sensor 30 a or 19 a and a temperature sensor 32 a / 21 a in the tubing 12 or 12 a are in communication with a pressure transducer 56 and a temperature transducer 57 .
  • the microprocessor 58 communicates with the power management system 52 , the pressure transducer 56 , and temperature transducer 57 adjusting the oxygen flow rate (sensed at sensor 54 ) to the wound site per programmed algorithms to optimally meet changes in the patients oxygen wound healing requirements.
  • FIGS. 6-6B the electrochemical oxygen generator/concentrator 11 is illustrated.
  • FIG. 6 is a top plan view of concentrator 11 showing the cathode plate 70 overlaying the anode plate 72 .
  • FIG. 6A is a side elevation view of the concentrator 11 .
  • Each of the charged plates has a carbon backed metalized substrate with a titanium mesh plated on the carbon membrane. This provides a complete coverage area for electrical conductance to a Nafion® oxygen transfer membrane.
  • National® is a registered trademark of DuPont and is a sulfonated tetrafluroethylene copolymer.
  • National® is well known in the art as a proton conductor for proton exchange membranes (PEM).
  • a Nafion 212 membrane is preferred in the present invention.
  • FIG. 6B is an exploded perspective view of the concentrator 11 .
  • the PEM membrane 74 is compressed fully (40-60 ft-lbs force) between the cathode 70 and the anode 72 .
  • a gasket seal 76 may be utilized with flange bolting 78 .
  • a 304 L stainless steel needle discharge valve 80 with viton seats is machined for attachment into the anode plate 72 using a viton O-ring (not shown).
  • the preferred membrane 84 in the present invention is a Gore-Tex® fabric. (Gore-Tex® is the registered trademark of W.L. Gore & Associates.) Concentrated O 2 is discharged out discharge valve 80 which communicates with discharge 54 in housing 13 .
  • FIG. 7 A firmware flow chart for the present invention is illustrated in FIG. 7 .
  • the microprocessor 58 calibrates 92 all sensors and the PEM cell. Because every PEM cell and each sensor has its own particular functional characteristics, the present invention calibrates the sensors and cell to ensure precise flow rates.
  • the microprocessor gets the desired 95 flow rate from the user.
  • the microprocessor calculates the voltage and current to output from the PEM the set desired flow rate 96 .
  • the microprocessor receives input from the flow rate sensor 54 and determines if the set flow rate has been reached 97 , if not the processor again seeks to recalibrate the sensors and the PEM cell. If the set flow rate is reached 97 , then the microprocessor enters a proportional control mode 98 .
  • the flow rate may be adjusted based upon input from the temperature monitoring system and the pressure monitoring system.
  • the microprocessor also displays the flow rate and the temperature on the monitor display screen 68 .
  • the microprocessor continuously tests the actual flow rate to ensure that it is maintained 99 using a feedback loop which looks at variations in sensor and PEM cell efficiencies.
  • a wound monitoring system is contemplated.
  • Patient data and therapy commands are communicated to the device by the care giver or patient for processing by means of a data input key pad 64 and function control buttons 65 .
  • a data port 66 may be used to upload or download data.
  • the monitoring system allows for collection and monitoring of key medical parameters to aid the caregiver in managing the patient care and potentially accelerate the healing process with improved access to more data.
  • Available patient data and device functions are displayed and where appropriate are visually and audibly alarmed on the device function display screen 68 .
  • a digital camera 69 may also be utilized to aid the monitoring process visually tracking the wound closure progress.

Abstract

A wound treatment system includes a housing that defines an oxygen outlet. An oxygen production subsystem is included in the housing and coupled to the oxygen outlet. A control subsystem is coupled to the oxygen production subsystem and configured to receive pressure information that is indicative of a pressure in a restricted airflow enclosure that is coupled to the oxygen outlet. The control subsystem then uses the pressure information to control power provided to the oxygen production subsystem in order to control an oxygen flow that is created by the oxygen production subsystem and provided through the oxygen outlet to the restricted airflow enclosure.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. patent application Ser. No. 12/738,905, filed Nov. 11, 2010, which is a national stage entry of PCT Application No. PCT/US09/02523, filed Apr. 23, 2009, which claims the benefit of U.S. patent application Ser. No. 12/288,873 (now U.S. Pat. No. 8,287,506), filed Oct. 24, 2008, which claims the benefit of U.S. Provisional Application No. 61/000,695, filed Oct. 26, 2007. The contents of each referenced application are hereby incorporated by reference herein.
BACKGROUND
This invention relates to tissue treatment systems, specifically to non-invasive tissue oxygenation systems for accelerating the healing of damaged tissue and promoting tissue viability. When skin is damaged a wound results and a four phase healing process begins. Optimal metabolic function of these cells to repopulate the wound requires that oxygen be available for all phases of wound healing. The more layers of tissue that are damaged the greater the risk for complications to occur in the wound healing process.
Difficult-to-heal wounds encounter barriers to the wound healing process and typically experience delays in one or more of the last three phases of wound healing. One of the most common contributing factors to venous leg ulcers, diabetic foot ulcers and pressure ulcers experiencing delays in the healing process is the problem of chronic wound ischemia. Chronic wound ischemia a pathological condition that restricts blood supply, oxygen delivery and blood request for adequate oxygenation of tissue, inhibiting normal wound healing.
In practice the standard of care for treating difficult-to-heal wounds typically involves the use of an advanced wound dressing or combination of advanced wound dressings providing a dressing treatment system. An advanced dressing is positioned on the wound site or on the wound site and the surrounding intact skin providing a wound site enclosure. An advanced wound dressing is typically comprised of materials having properties for promoting moist wound healing, managing wound exudate and helping control wound bioburden. The typical material components in combination further include properties for providing limited moisture vapor permeability. The lower the dressing's moisture vapor permeability or more occlusive the dressing the lower the amount of ambient air and the respective lower amount of oxygen is thereby available to the wound bed. 100% oxygen exerts a partial pressure of 760 mm Hg. Ambient air is comprised of about 21% oxygen thereby exerting a partial pressure of oxygen at about 159 mm Hg. A typical advanced wound dressing or wound dressing system comprised of lower moisture vapor permeable materials impacts the available oxygen for the wound site thereby limiting the partial pressure of oxygen at the enclosed wounds site at about 10 mm Hg to 60 mm Hg. Fresh air is provided to the wound site only when the dressing is changed. A dressing may remain covering the wound site for up to seven days before a dressing change is required. The moisture vapor permeability property of an advanced wound dressing providing a reduced oxygen wound environment thereby works against the optimal metabolic function of cells to repopulate the wound which requires that oxygen be available for all phases of wound healing.
Prior art methods of tissue oxygenation for difficult-to-heal wounds include topical hyperbaric oxygen applied intermittently or continuously. Intermittent topical hyperbaric oxygen is a method of tissue oxygenation comprising of a sealed extremity or partial body chamber and a connected source of high flow pure oxygen whereby the affected limb or affected body area is positioned in a sealed extremity chamber or partial body chamber so that the oxygen source supplying the chamber is providing the patient topically up to 100% oxygen at flow rates that may exceed 300 liters per hour pressurizing the interior of the chamber up to 1.05% normal atmospheric pressure thereby increasing the available oxygen for cellular processing at affected wound site. During the oxygen application, the partial pressure of oxygen exerted inside the topical or partial body chamber may attain 798 mm Hg. Topical hyperbaric oxygen is applied for about 90 minutes. Prior art also teaches a plurality of methods to apply topically hyperbaric oxygen intermittently. A partial body chamber for treating sacral wounds has been described in U.S. Pat. No. 4,328,799 to LoPiano (1980) whereby oxygen is applied from a stationary supply tank into the interior of the chamber through connected tubing. A similar method of applying topical hyperbaric oxygen is described in U.S. Pat. No. 5,478,310 to Dyson-Cantwell (1995) whereby oxygen is applied from a stationary supply tank into the interior of the disposable extremity chamber through connected tubing. These and similar methods of applying intermittent topical hyperbaric oxygen are restrictive, cumbersome, can only supply oxygen to the affected area intermittently with no systemic application, and can only be applied with a minimal increase in atmospheric pressure (about 5%). Therefore the effect of the oxygen therapy on the wound can be minimal which is evidenced by the lack of commercial success from topical hyperbaric oxygen extremity chambers.
Both U.S. Pat. No. 5,578,022 to Scherson (1996) and U.S. Pat. No. 5,788,682 to Maget (1998) describe disposable devices utilizing transmission of gases in ionic form through ion specific membranes to apply supplemental oxygen directly to the wound bed. These devices are described as battery powered, disposable, oxygen producing bandages and methods that are applied directly over the wound. They both include electrochemical oxygen generation using variations of the same 4 electron formula originally developed for NASA in U.S. Pat. No. 3,489,670 to Maget (1970). The amount of oxygen that can be applied to the wound is typically 3 milliliters per hour. Specific oxygen flow rates are generated by means of corresponding specific, preselected battery sizes and specific prescribed amperages. Prior art describes disposable devices are either “on or off.” The prior art describes disposable devices without means to sense temperature changes in the wound site oxygen environment. Prior art does not provide a means to deliver a varying (adjustable) oxygen flow rate without requiring the patient to obtain and apply a new device with a new battery having a specific amperage. Additional limitations are also associated with the use of a fixed non-variable oxygen flow rate.
No prior art low dose tissue oxygenation device provides continuous oxygen adjustability to a patient's wound(s) creating a controlled hyperoxia and hypoxia wound environment for damaged tissue to accelerate wound healing and promote tissue viability. Specifically, nothing in the prior art teaches continuous oxygen adjustability based on actual flow rate, partial pressures at the wound site, and temperatures at the wound site.
SUMMARY
The invention is an improved low dose tissue oxygenation device and wound monitoring system. The present invention generally comprises an oxygen delivery tube for placement at the wound bed and a wound dressing covering the tubing and wound site for restricted air flow enclosure. The tubing may have multiple holes at or near the distal end of the tubing. The tubing may include a generally flat, flexible, oxygen-permeable tape or membrane section attached at the distal end of the tube. The tubing may be flexible with a kink resistant inner lumen. The tubing may have a temperature sensor. The tubing may have a pressure sensor. The tubing may include a partial pressure of oxygen sensor. The proximal end of the tubing is connected to a source of oxygen. The proximal end of the tubing may have a port Leur-type locking mechanism for an airtight seal during application of the oxygen and for removal from the oxygen source during application a dressing. A source of oxygen is in communication with the proximal and distal ends of the tube. A source of oxygen may be an electrochemical oxygen concentrator supplied by alternating or direct current, a power management device and its power management protocol. The variable electrochemical oxygen concentrator is used in accordance with the present invention by varying the oxygen flow rate to meet varying target parameters at the wound site. The oxygen flow rate is adjusted by a system that periodically or continuously monitors the wound bed pressure and temperature environment or the tubing pressure and adjusting the oxygen flow rate in accordance to target set points. Adjusting oxygen flow in response to monitored changes in wound site oxygen and target oxygen pressure and temperature protocols provides a controlled hyperoxia wound environment which may shorten the healing process.
In some embodiments, the device may have a backlight display terminal or touch screen liquid crystal display, a data input key pad or device function control buttons, a wound temperature monitoring system, a battery or oxygen pressure alarm system, a digital camera, a patient data input and memory system and/or a data port or wireless data access.
BRIEF DESCRIPTION OF THE DRAWINGS
A more complete understanding of the present disclosure and advantages thereof may be acquired by referring to the following description taken in conjunction with the accompanying figures, wherein:
FIG. 1 is a perspective view of an embodiment of a tissue oxygenation system of the present invention.
FIG. 1A is a cross section view of a wound site showing a distal end of a oxygen delivery tube of the present invention
FIG. 2 is a side perspective view of the distal end of an embodiment of the tubing of the present invention showing a generally flat, flexible, oxygen-permeable tape or membrane section affixed to the tubing.
FIG. 2A is an end view of another embodiment of the tubing of the present invention.
FIG. 3 is side elevation view of the distal end of the oxygen delivery tubing of the embodiment of FIG. 2A of the present invention
FIG. 4 is a perspective view of a handset of the present invention.
FIG. 5 is a flow chart illustrating the process of the present invention.
FIG. 6 is a top plan view of the electrolyzer/concentrator of the present invention.
FIG. 6A is a side elevation plan view of the electrolyzer of FIG. 6.
FIG. 6B is an exploded perspective view of the electrolyzer of FIG. 6.
FIG. 7 is a processor firmware flow chart of the present invention.
While the present invention is susceptible to various modifications and alternative forms, specific exemplary embodiments thereof have been shown by way of example in the drawings and are herein described in detail. It should be understood, however, that the description herein of specific embodiments is not intended to limit the invention to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.
DETAILED DESCRIPTION
A preferred embodiment of the present invention, tissue oxygenation system for the healing of damaged tissue and to promote tissue viability, will now be described in detail with reference to the figures.
FIG. 1 is a perspective view of several primary components of the present invention according to the preferred embodiment. The present invention includes a monitoring unit 10, an electrochemical oxygen concentrator 11, oxygen delivery tubing 12, moisture absorbent dressing 14, and vapor dressing 16. Preferably, oxygen delivery tubing 12 is connected at the proximal end 15 of the long, kink resistant tubing to the monitoring unit 10. The monitoring unit 10 has a small, lightweight housing which is portable and may be discretely worn by the patient in a pocket or attached to a belt.
The monitoring unit 10 includes within the housing 13 a microprocessor 58 (see FIGS. 5 and 7), a power management system 52, pressure 56 and temperature 57 sensor interface(s), a flow rate sensor 54, an input port 62 and a user entry port 66. The electrochemical oxygen concentrator 11 is disposed within the housing 13. The microprocessor 58 functions to control power, collect various readings from the flow, pressure, and temperature sensors controls ionic purification of room air by the electrochemical oxygen concentrator for delivery to the tubing, and controls the informational display on the monitoring unit 10. Preferably, the microprocessor 58 is capable of receiving data through the user entry port and the input port, including information related to specific patients and re-programming information if there is a system malfunction with the device.
As may be further seen in FIGS. 1A and 2, the distal end 17 of the tubing 12 has a soft, flexible, oxygen permeable tape or membrane section 29 placed on the damaged tissue or wound site 20 of a patient's limb 19 covered with a moisture absorbent dressing 14 and further covered by a reduced vapor pressure, permeable, occlusive dressing 16.
In a first embodiment, oxygen is delivered to the wound site 20 through a kink-resistant tube 12 connected at the proximal end 15 to the outlet of the oxygen concentrator at the monitor unit housing. On the distal end 17 of the tubing 12 is connected soft, flexible oxygen-permeable flat tape or membrane 29. Extending through the lumen of the tube are several sensor wires 30 and 32. These wires communicate from temperature sensor 30 a and oxygen partial pressure sensor 32 a disposed at the wound site to temperature 57 and pressure 56 transducers in the monitoring unit with the transducers providing input to the microprocessor 58 as would be understood by one of ordinary skill in the art.
Alternatively, tubing 12 a (FIG. 2A) preferably has several lumens, pressure 21 and temperature 19 sensors, and other such sensors as may be required to effectively monitor wound treatment, disposed therein. Specifically, FIG. 2A illustrates an end view of the tubing 12 a, and depicts a tubing with a length capable of connecting to the output side of electrochemical oxygen concentrator 11 housed within monitoring unit 10. Such tubing lengths allow the monitoring unit to be worn discretely and continuously deliver oxygen to the wound site 20. An inner lumen, or bore 18 a, of the tubing is a star like configuration to prevent kinking of the tubing and still allows oxygen flow if bent. The oxygen partial pressure sensor 19 a at the wound site is disposed within the tubing and is in communication with a pressure monitoring system including transducer 58 allowing for oxygen flow rate adjustment, visual pressure display, and out of range alarm. A temperature sensor 21 a is also disposed within the tubing at the wound site 20 and is in communication with a temperature monitoring system including transducer 57 allowing for visual display of temperature, an out of range alarm, and allowing for oxygen adjustment via the microprocessor 58 as is appropriate.
FIG. 3 is a side view of the distal end of alternative tubing 12 a, which includes a plurality of holes 23 formed along the side of the distal end of the tubing to aid in the delivery of oxygen to the wound. In use, the oxygen flows F through the tubing to the wound site and may enter the wound bed through the multiple holes 23. The oxygen may also flow through the distal end of star shaped lumen 18 a, however, the multiple holes at the distal end of the tubing allow for improved flow of oxygen to the wound site 20.
FIG. 1A shows a wound site 20, with the distal end 17 of the oxygen delivery tubing 12 having the oxygen distribution tape 29 placed over the wound site 20. The tape 29 is placed centrally on the wound site for optimal delivery of oxygen to the damaged tissue. A moisture absorbent dressing 14 is placed at the wound site covering the tape end of the oxygen delivery tubing 12 and wound site. One skilled in the art will appreciate that moisture absorbent dressing is typical standard of care protocol for a difficult-to-heal wound. A reduced moisture vapor permeable dressing 16 covers the moisture absorbent dressing 14, tape end of tubing 12 and wound site 20, creating a restricted airflow enclosure. Preferably the reduced moisture vapor permeable dressing 16 is transparent and may be described to as an occlusive dressing. The occlusive dressing traps the oxygen over the wound site to create and maintain oxygen rich environment. The local partial pressure of oxygen at the wound site 20 may be increased from a low range of 10 to 60 mm Hg to an oxygen rich environment range of 200 to 760 mm HG. The increased available oxygen is metabolized at the cellular level and will stimulate an increase in growth factors, epithelialization, granulation tissue, glycosaminoglycan production, and collagen synthesis. The oxygen partial pressure at the wound site is communicated to the pressure monitoring transducer 57 in the housing 13. The transducer supplies data to the microprocessor 58 which controls the power flow (amperage) to the concentrator 11. The concentrator may increase or decrease the O2 flow rate.
FIG. 4 is a perspective view of a handset housing the major components of the present invention. FIG. 5 is a flow chart of the present invention.
As shown in FIGS. 4 and 5, in use, the monitor housing 13 draws in room air 50 with about 21% oxygen through the air inlet 40 by means of an electrochemical process. The room air passes through an ion exchange oxygen concentrator 11, which concentrates the oxygen level of the room air to create a mixture that is 99% pure oxygen. The power management system 52 controls the electrical current supplied to the ion exchange oxygen concentrator 11, thereby making the oxygen flow rate conform to the amount of current supplied to the ion exchange oxygen concentrator, i.e., increasing electrical current increases the electrochemical process and thereby increases the respective oxygen flow rate to the wound site 20 and decreasing the electrical current decreases the electrochemical process thereby decreasing the respective oxygen flow rate to the wound site. It should be noted that the power management system 52 includes lithium batteries (7.4 v) and a regulator which varies the amperage over a range from approximately 15 milliamps to approximately 150 milliamps. This range of current variation results in O2 flow rates in the range of approximately 1.0 milliliters/hour to approximately 15.0 milliliters/hour.
The concentrated O2 then exits the housing through the oxygen delivery port 54. The proximal end 15 of the oxygen delivery tubing 12 is connected with an oxygen delivery port 54 with Leur-type locking fitting. The locking fitting is engaged to maintain an airtight seal with the tubing.
As illustrated in FIGS. 2 and 5, a pressure sensor 30 a or 19 a and a temperature sensor 32 a/21 a in the tubing 12 or 12 a are in communication with a pressure transducer 56 and a temperature transducer 57. The microprocessor 58 communicates with the power management system 52, the pressure transducer 56, and temperature transducer 57 adjusting the oxygen flow rate (sensed at sensor 54) to the wound site per programmed algorithms to optimally meet changes in the patients oxygen wound healing requirements.
Turning to FIGS. 6-6B, the electrochemical oxygen generator/concentrator 11 is illustrated. FIG. 6 is a top plan view of concentrator 11 showing the cathode plate 70 overlaying the anode plate 72. FIG. 6A is a side elevation view of the concentrator 11.
Each of the charged plates has a carbon backed metalized substrate with a titanium mesh plated on the carbon membrane. This provides a complete coverage area for electrical conductance to a Nafion® oxygen transfer membrane. Nation® is a registered trademark of DuPont and is a sulfonated tetrafluroethylene copolymer. Nation® is well known in the art as a proton conductor for proton exchange membranes (PEM). A Nafion 212 membrane is preferred in the present invention.
FIG. 6B is an exploded perspective view of the concentrator 11. The PEM membrane 74 is compressed fully (40-60 ft-lbs force) between the cathode 70 and the anode 72. To provide proper sealing of the concentrator, a gasket seal 76 may be utilized with flange bolting 78. A 304L stainless steel needle discharge valve 80 with viton seats is machined for attachment into the anode plate 72 using a viton O-ring (not shown).
Electrical contact and transfer to the plates is accomplished by attaching a copper strip to the titanium mesh substrate. The compressive force applied provides the necessary adhesion to the surfaces of the two metals. The strips are then attached to the charge plates with epoxy.
Ambient air enters the concentrator through inlet 82 which is covered by a polarized membrane 84 which allows water vapor to pass in one direction only and maintain the encapsulation of other gases (mainly hydrogen). The preferred membrane 84 in the present invention is a Gore-Tex® fabric. (Gore-Tex® is the registered trademark of W.L. Gore & Associates.) Concentrated O2 is discharged out discharge valve 80 which communicates with discharge 54 in housing 13.
A firmware flow chart for the present invention is illustrated in FIG. 7. When the monitoring unit 10 is started or powered up 90, the microprocessor 58 calibrates 92 all sensors and the PEM cell. Because every PEM cell and each sensor has its own particular functional characteristics, the present invention calibrates the sensors and cell to ensure precise flow rates.
If the calibration is successful 94, then the microprocessor gets the desired 95 flow rate from the user. The microprocessor calculates the voltage and current to output from the PEM the set desired flow rate 96. The microprocessor receives input from the flow rate sensor 54 and determines if the set flow rate has been reached 97, if not the processor again seeks to recalibrate the sensors and the PEM cell. If the set flow rate is reached 97, then the microprocessor enters a proportional control mode 98. The flow rate may be adjusted based upon input from the temperature monitoring system and the pressure monitoring system. The microprocessor also displays the flow rate and the temperature on the monitor display screen 68.
In the proportional control mode, the microprocessor continuously tests the actual flow rate to ensure that it is maintained 99 using a feedback loop which looks at variations in sensor and PEM cell efficiencies.
In another embodiment of the invention a wound monitoring system is contemplated. Patient data and therapy commands are communicated to the device by the care giver or patient for processing by means of a data input key pad 64 and function control buttons 65. A data port 66 may be used to upload or download data. The monitoring system allows for collection and monitoring of key medical parameters to aid the caregiver in managing the patient care and potentially accelerate the healing process with improved access to more data. Available patient data and device functions are displayed and where appropriate are visually and audibly alarmed on the device function display screen 68. A digital camera 69 may also be utilized to aid the monitoring process visually tracking the wound closure progress.

Claims (20)

What is claimed is:
1. A wound treatment system, comprising:
a housing that defines an oxygen outlet;
an oxygen production subsystem that is included in the housing and coupled to the oxygen outlet; and
a control subsystem that is coupled to the oxygen production subsystem and configured to:
receive pressure information that is indicative of a pressure in a restricted airflow enclosure that is coupled to the oxygen outlet; and
control, using the pressure information, power provided to the oxygen production subsystem in order to control an oxygen flow that is created by the oxygen production subsystem and provided through the oxygen outlet to the restricted airflow enclosure.
2. The system of claim 1, further comprising:
a power subsystem that is located in the housing, coupled to the oxygen production subsystem and the control subsystem, and configured to provide the power to the oxygen production subsystem.
3. The system of claim 1, further comprising:
a pressure sensor that is located in the housing and configured to provide the pressure information to the control subsystem.
4. The system of claim 1, further comprising:
a flow rate sensor that is located in the housing and coupled to the oxygen production subsystem and the control subsystem, wherein the control subsystem is configured to:
receive, from the flow rate sensor, flow rate information that is indicative of the oxygen flow created by the oxygen production subsystem; and
control, using the flow rate information, power provided to the oxygen production subsystem in order to control the oxygen flow created by the oxygen production subsystem and provided through the oxygen outlet to the restricted airflow enclosure.
5. The system of claim 1, further comprising:
a display subsystem that is included on the housing and coupled to the control subsystem; and
an input subsystem that is included on the housing and coupled to the control subsystem, wherein the control subsystem is configured to:
provide, for display on the display subsystem, display information; and
receive, from the input subsystem, input information.
6. The system of claim 5, wherein the input subsystem includes a touch screen input subsystem that is integrated with the display subsystem.
7. The system of claim 1, further comprising:
a data communication subsystem that is coupled to the control subsystem, wherein the control subsystem is configured to perform at least one of:
downloading, using the data communication subsystem, data for use in at least one subsequent operation of the system; and
uploading, using the data communication subsystem, data generated during at least one previous operation of the system.
8. A method for treating wounds, comprising:
receiving, by a control subsystem from a pressure sensor, pressure information that is indicative of a pressure in a restricted airflow enclosure;
controlling, by the control subsystem using the pressure information, power provided to an oxygen production subsystem that is coupled to the restricted airflow enclosure; and
creating, by the oxygen production subsystem using the power controlled by the control subsystem, oxygen such that the oxygen is provided to the restricted airflow enclosure.
9. The method of claim 8, further comprising:
providing, by a power subsystem to the oxygen production subsystem, the power that is controlled by the control subsystem.
10. The method of claim 8, further comprising:
receiving, by the control subsystem from a flow rate sensor, flow rate information that is indicative of an oxygen flow rate of the oxygen created by the oxygen production subsystem;
controlling, by the control subsystem using the flow rate information, power provided to the oxygen production subsystem in order to control the oxygen flow rate of the oxygen created by the oxygen production subsystem and provided to the restricted airflow enclosure.
11. The method of claim 8, further comprising:
providing, by the control subsystem for display on a display subsystem, display information; and
receiving, by the control subsystem from an input subsystem, input information.
12. The method of claim 11, wherein the input subsystem includes a touch screen input subsystem that is integrated with the display subsystem.
13. The method of claim 8, further comprising:
downloading, by the control subsystem using a data communication subsystem, data for use in subsequently treating at least one wound; and
uploading, by the control subsystem using the data communication subsystem, data generated during at least one previous wound treatment.
14. A wound treatment system, comprising:
a processing system; and
a memory system that is coupled to the processing system and that includes instructions that, when executed by the processing system, cause the processing system to perform operations including:
receiving pressure information that is indicative of a pressure in a restricted airflow enclosure; and
controlling, using the pressure information, power provided to an oxygen production subsystem in order to control an oxygen flow that is created by the oxygen production subsystem and provided to the restricted airflow enclosure.
15. The method of claim 14, wherein the operations further comprise:
receiving flow rate information that is indicative of the oxygen flow created by the oxygen production subsystem; and
controlling, using the flow rate information, power provided to the oxygen production subsystem in order to control the oxygen flow that is created by the oxygen production subsystem and provided to the restricted airflow enclosure.
16. The method of claim 14, wherein the operations further comprise:
providing, for display on a display subsystem, display information.
17. The method of claim 16, wherein the operations further comprise:
receiving, from an input subsystem, input information.
18. The system of claim 17, wherein the input subsystem includes a touch screen input subsystem that is integrated with the display subsystem.
19. The system of claim 14, wherein the operations further comprise:
downloading, using a data communication subsystem, data for use in at least one subsequent operation of the system.
20. The system of claim 14, wherein the operations further comprise:
uploading, by the control subsystem using the data communication subsystem, data generated during at least one previous operation of the system.
US15/642,833 2007-10-26 2017-07-06 Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability Active 2029-12-08 US10632018B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/642,833 US10632018B2 (en) 2007-10-26 2017-07-06 Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69507P 2007-10-26 2007-10-26
US12/288,873 US8287506B2 (en) 2007-10-26 2008-10-24 Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
PCT/US2009/002523 WO2010047732A1 (en) 2008-10-24 2009-04-23 Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
US73890510A 2010-11-11 2010-11-11
US15/642,833 US10632018B2 (en) 2007-10-26 2017-07-06 Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2009/002523 Continuation WO2010047732A1 (en) 2007-10-26 2009-04-23 Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
US12/738,905 Continuation US9730838B2 (en) 2008-10-24 2009-04-23 Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability

Publications (2)

Publication Number Publication Date
US20170296392A1 US20170296392A1 (en) 2017-10-19
US10632018B2 true US10632018B2 (en) 2020-04-28

Family

ID=40583785

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/288,873 Active 2030-09-19 US8287506B2 (en) 2007-10-26 2008-10-24 Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
US12/738,905 Active 2033-01-21 US9730838B2 (en) 2008-10-24 2009-04-23 Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
US15/642,833 Active 2029-12-08 US10632018B2 (en) 2007-10-26 2017-07-06 Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US12/288,873 Active 2030-09-19 US8287506B2 (en) 2007-10-26 2008-10-24 Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
US12/738,905 Active 2033-01-21 US9730838B2 (en) 2008-10-24 2009-04-23 Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability

Country Status (7)

Country Link
US (3) US8287506B2 (en)
EP (1) EP2340001B1 (en)
JP (1) JP5579188B2 (en)
CN (1) CN102202618B (en)
AU (1) AU2009307077B2 (en)
CA (1) CA2681155C (en)
WO (1) WO2010047732A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11529503B2 (en) * 2007-10-26 2022-12-20 Electrochemical Oxygen Concepts, Inc. Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027834A2 (en) * 2003-09-12 2005-03-31 Z-Medica Corporation Partially hydrated hemostatic agent
US20060178609A1 (en) 2005-02-09 2006-08-10 Z-Medica, Llc Devices and methods for the delivery of molecular sieve materials for the formation of blood clots
CA2597940A1 (en) 2005-02-15 2006-08-24 Virginia Commonwealth University Mineral technologies (mt) for acute hemostasis and for the treatment of acute wounds and chronic ulcers
US8938898B2 (en) * 2006-04-27 2015-01-27 Z-Medica, Llc Devices for the identification of medical products
US7604819B2 (en) 2006-05-26 2009-10-20 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US8202532B2 (en) 2006-05-26 2012-06-19 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US7968114B2 (en) 2006-05-26 2011-06-28 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US20080317831A1 (en) * 2007-06-21 2008-12-25 Denny Lo Hemostatic sponge and method of making the same
WO2009032884A1 (en) * 2007-09-05 2009-03-12 Z-Medica Corporation Wound healing with zeolite-based hemostatic devices
US8287506B2 (en) * 2007-10-26 2012-10-16 Electrochemical Oxygen Concepts, Inc. Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
GB2470358B (en) * 2009-05-18 2014-05-14 Inotec Amd Ltd Hyperbaric dressing and method
US9357764B2 (en) * 2009-06-18 2016-06-07 Giner, Inc. System for fluid perfusion of biological matter comprising tissue
US10091985B2 (en) * 2009-06-18 2018-10-09 Giner, Inc. Perfusing an organ with an in situ generated gas
US20110015565A1 (en) * 2009-07-15 2011-01-20 Hursey Francis X Gas dispenser with therapeutic agent
US9511196B2 (en) 2009-12-31 2016-12-06 Ohio University Systems and methods for promoting wound healing
US8858969B2 (en) 2010-09-22 2014-10-14 Z-Medica, Llc Hemostatic compositions, devices, and methods
EP2785297B1 (en) 2011-11-28 2018-01-10 Hyposkin APS A system for reduced scarring of wounds
GB201206907D0 (en) 2012-04-19 2012-06-06 Inotec Amd Ltd Oxygen distributor
WO2013191836A1 (en) 2012-06-22 2013-12-27 Z-Medica, Llc Hemostatic devices
US9919140B2 (en) 2012-10-05 2018-03-20 University Of Southern California Implantable oxygenator with self-contained electrolyte
ES2655788T3 (en) 2013-01-28 2018-02-21 Mölnlycke Health Care Ab Suction device
CN105073077A (en) 2013-02-12 2015-11-18 电化学氧概念公司 Dressing for wound treatment
EP3013407B1 (en) * 2013-06-29 2024-01-24 Vaporox, Inc. Medical treatment system
CN103393402B (en) * 2013-07-01 2016-06-29 西安交通大学 A kind of wound surface dressing binder pressure monitor of Portable burn and wound
AU2014326794B2 (en) 2013-09-24 2019-03-21 Giner, Inc. System for gas treatment of a cell implant
WO2015142528A1 (en) 2014-03-19 2015-09-24 Adrian Pelkus Portable medical treatment system and method of use
US9770369B2 (en) 2014-08-08 2017-09-26 Neogenix, Llc Wound care devices, apparatus, and treatment methods
US10245392B2 (en) * 2014-08-08 2019-04-02 Neogenix, Llc Oxygen concentrating device, wound care apparatus, and treatment methods
AU2016256436B2 (en) * 2015-04-28 2020-10-22 Convatec Technologies Inc. Antibacterial nanofibres
CN104840174A (en) * 2015-05-18 2015-08-19 中国人民解放军第四军医大学 Visible skin-grafting instrument
CN104939796A (en) * 2015-05-18 2015-09-30 中国人民解放军第四军医大学 Visual pocket used for skin grafting
CN104840173A (en) * 2015-05-18 2015-08-19 中国人民解放军第四军医大学 Heat insulation cashmere material for skin-grafting piece visual bag
EP3361950A4 (en) * 2015-10-13 2019-03-20 HyperMed Imaging, Inc. Compact light sensors for surgical applications and shock detection
CA3005473C (en) * 2015-12-07 2023-03-28 Electrochemical Oxygen Concepts, Inc. Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
CA3043468C (en) 2016-11-15 2021-06-22 Giner Life Sciences, Inc. Percutaneous gas diffusion device suitable for use with a subcutaneous implant
RU2019114843A (en) 2016-11-15 2020-11-16 Джинер Лайф Сайенс, Инк. SELF-REGULATING ELECTROLYTIC GAS GENERATOR AND IMPLANTATION SYSTEM CONTAINING IT
CN112384267B (en) 2018-05-17 2022-08-09 吉纳生命科学公司 Electrolytic gas generator with combined lead and gas port terminals
US11432965B2 (en) * 2018-10-05 2022-09-06 Deborah Kantor Medical bandage for the head, a limb or a stump
US11504466B2 (en) 2019-04-08 2022-11-22 Jeffrey Hegg Medical gauze and gas flow assembly and method of applying a medical gauze with gas flow on a wound
WO2020214698A1 (en) 2019-04-15 2020-10-22 Electrochemical Oxygen Concepts, Inc. Wound oxygen treatment system
EP4243902A1 (en) 2020-11-16 2023-09-20 Vaporox, Inc. Multistage vaporizer for medical treatment system

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489670A (en) 1964-07-29 1970-01-13 Gen Electric Process for gas purification
US5578022A (en) 1995-04-12 1996-11-26 Scherson; Daniel A. Oxygen producing bandage and method
US5788682A (en) 1995-04-28 1998-08-04 Maget; Henri J.R. Apparatus and method for controlling oxygen concentration in the vicinity of a wound
US6010317A (en) 1998-09-01 2000-01-04 Baxter International Inc. Electrochemical cell module having an inner and an outer shell with a nested arrangement
US6071267A (en) 1998-02-06 2000-06-06 Kinetic Concepts, Inc. Medical patient fluid management interface system and method
US6171368B1 (en) 1998-11-06 2001-01-09 Med-E-Cell Gas extraction from closed containers
JP2002524109A (en) 1998-08-07 2002-08-06 ヒル−ロム,インコーポレイティド Wound healing equipment
US20030083610A1 (en) 2001-02-01 2003-05-01 Mcgrath Terrence S. Compositions and method of tissue superoxygenation
JP2005511205A (en) 2001-12-12 2005-04-28 オクシファスト コーポレーション Oxygen production device for wound care
US7014630B2 (en) 2003-06-18 2006-03-21 Oxyband Technologies, Inc. Tissue dressing having gas reservoir
US20060225737A1 (en) * 2005-04-12 2006-10-12 Mr. Mario Iobbi Device and method for automatically regulating supplemental oxygen flow-rate
WO2006122169A2 (en) 2005-05-10 2006-11-16 Ogenix Corporation Novel portable electrochemical devices for dual action wound healing
US20060287632A1 (en) * 2001-12-12 2006-12-21 Srinivasan Sarangapani Oxygen producing device for woundcare
US20070299412A1 (en) 2005-08-08 2007-12-27 Vogel Richard C Wound Irrigation Device
US20080003299A1 (en) 2006-06-29 2008-01-03 Trotter Patrick J Methods for the treatment of wounds
US7316857B1 (en) 2004-06-28 2008-01-08 Swanson Steven T Miniature electrochemical gas generator and power source
US7322971B2 (en) 2003-02-07 2008-01-29 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Surgical drain with sensors for monitoring internal tissue condition by transmittance
US20080308100A1 (en) 2005-07-07 2008-12-18 Ric Investments, Llc. System and method for determining humidity in a respiratory treatment system
US20130144227A1 (en) 2011-11-23 2013-06-06 Christopher Brian Locke Reduced-pressure systems, methods, and devices for simultaneously treating a plurality of tissue sites

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62129052A (en) * 1985-11-29 1987-06-11 ユニコロイド株式会社 Wound covering material
US8100956B2 (en) * 2006-05-09 2012-01-24 Thermotek, Inc. Method of and system for thermally augmented wound care oxygenation
US8287506B2 (en) 2007-10-26 2012-10-16 Electrochemical Oxygen Concepts, Inc. Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
EP2244746B2 (en) * 2008-02-27 2019-01-02 Aplion Medical Corporation Wound dressing with uniform distribution

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489670B1 (en) 1964-07-29 1985-12-10 Gen Electric
US3489670A (en) 1964-07-29 1970-01-13 Gen Electric Process for gas purification
JP2000507459A (en) 1995-04-12 2000-06-20 バーク,メルビン,アイ. Oxygen generating bandage
US5578022A (en) 1995-04-12 1996-11-26 Scherson; Daniel A. Oxygen producing bandage and method
US5788682A (en) 1995-04-28 1998-08-04 Maget; Henri J.R. Apparatus and method for controlling oxygen concentration in the vicinity of a wound
US6071267A (en) 1998-02-06 2000-06-06 Kinetic Concepts, Inc. Medical patient fluid management interface system and method
JP2002524109A (en) 1998-08-07 2002-08-06 ヒル−ロム,インコーポレイティド Wound healing equipment
US6010317A (en) 1998-09-01 2000-01-04 Baxter International Inc. Electrochemical cell module having an inner and an outer shell with a nested arrangement
US6171368B1 (en) 1998-11-06 2001-01-09 Med-E-Cell Gas extraction from closed containers
US20030083610A1 (en) 2001-02-01 2003-05-01 Mcgrath Terrence S. Compositions and method of tissue superoxygenation
JP2004529090A (en) 2001-02-01 2004-09-24 ハイドロン テクノロジーズ,インク. Hyperoxygenated compositions and methods for supplying oxygen to tissue
JP2005511205A (en) 2001-12-12 2005-04-28 オクシファスト コーポレーション Oxygen production device for wound care
US20060287632A1 (en) * 2001-12-12 2006-12-21 Srinivasan Sarangapani Oxygen producing device for woundcare
US7322971B2 (en) 2003-02-07 2008-01-29 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Surgical drain with sensors for monitoring internal tissue condition by transmittance
US7014630B2 (en) 2003-06-18 2006-03-21 Oxyband Technologies, Inc. Tissue dressing having gas reservoir
US7263814B2 (en) 2003-06-18 2007-09-04 Oxyband Technologies, Inc. Method and apparatus for supplying gas to an area
US7316857B1 (en) 2004-06-28 2008-01-08 Swanson Steven T Miniature electrochemical gas generator and power source
US20060225737A1 (en) * 2005-04-12 2006-10-12 Mr. Mario Iobbi Device and method for automatically regulating supplemental oxygen flow-rate
WO2006122169A2 (en) 2005-05-10 2006-11-16 Ogenix Corporation Novel portable electrochemical devices for dual action wound healing
JP2008539966A (en) 2005-05-10 2008-11-20 オジニクス コーポレーション A novel portable electrochemical device for dual action wound treatment
US20080308100A1 (en) 2005-07-07 2008-12-18 Ric Investments, Llc. System and method for determining humidity in a respiratory treatment system
US20070299412A1 (en) 2005-08-08 2007-12-27 Vogel Richard C Wound Irrigation Device
US20080003299A1 (en) 2006-06-29 2008-01-03 Trotter Patrick J Methods for the treatment of wounds
US20130144227A1 (en) 2011-11-23 2013-06-06 Christopher Brian Locke Reduced-pressure systems, methods, and devices for simultaneously treating a plurality of tissue sites

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
International Search Report and Written Opinion dated Feb. 24, 2017 issued in co-pending PCT Application No. PCT/US16/65378 (18 pages).
Search Report issued from Japan Patent Office (and English translation) in Japanese Patent Application 2011-533156, dated Jun. 25, 2013, 9 pages.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11529503B2 (en) * 2007-10-26 2022-12-20 Electrochemical Oxygen Concepts, Inc. Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability

Also Published As

Publication number Publication date
EP2340001A1 (en) 2011-07-06
JP5579188B2 (en) 2014-08-27
WO2010047732A1 (en) 2010-04-29
CA2681155C (en) 2015-01-20
JP2012506292A (en) 2012-03-15
US20170296392A1 (en) 2017-10-19
AU2009307077B2 (en) 2015-04-30
US20090112170A1 (en) 2009-04-30
US20110054388A1 (en) 2011-03-03
CA2681155A1 (en) 2010-04-28
CN102202618B (en) 2014-09-03
US9730838B2 (en) 2017-08-15
EP2340001A4 (en) 2016-03-02
EP2340001B1 (en) 2020-06-03
CN102202618A (en) 2011-09-28
AU2009307077A1 (en) 2010-04-29
US8287506B2 (en) 2012-10-16

Similar Documents

Publication Publication Date Title
US10632018B2 (en) Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
US11529503B2 (en) Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
AU2010218186B2 (en) Oxygen-producing bandage with releasable oxygen source
EP3645103B1 (en) Wound oxygen supply system
EP3386581B1 (en) Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
AU2015201152B2 (en) Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
JP2024057069A (en) Wound oxygen supply system
CN113784737A (en) Oxygen therapy system for wounds

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: ELECTROCHEMICAL OXYGEN CONCEPTS, INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WELLS, MICHAEL C.;PARKER, MARK;CLARIUS, DANIEL J.;AND OTHERS;SIGNING DATES FROM 20100615 TO 20181011;REEL/FRAME:047138/0711

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4

AS Assignment

Owner name: VGM GROUP INC., IOWA

Free format text: SECURITY INTEREST;ASSIGNOR:ELECTROCHEMICAL OXYGEN CONCEPTS, INC.;REEL/FRAME:066939/0307

Effective date: 20240328